Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma

The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large‐cell lymphoma (ALCL) treated with doxorubicin‐based chemotherapy and radiotherapy. Forty‐six adult patients with early stage systemic ALCL received chemotherapy followed by radiotherapy. All pa...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2013-03, Vol.90 (3), p.195-201
Main Authors: Zhang, Xi-Mei, Li, Ye-Xiong, Wang, Wei-Hu, Jin, Jing, Wang, Shu-Lian, Liu, Yue-Ping, Song, Yong-Wen, Ren, Hua, Fang, Hui, Zhou, Li-Qiang, Chen, Bo, Qi, Shu-Nan, Liu, Qing-Feng, Lu, Ning-Ning, Liu, Xin-Fan, Yu, Zi-Hao
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
chemotherapy
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
early stage
Female
Gamma Rays
Humans
Lymph Nodes - drug effects
Lymph Nodes - pathology
Lymph Nodes - radiation effects
Lymphoma, Large-Cell, Anaplastic - drug therapy
Lymphoma, Large-Cell, Anaplastic - mortality
Lymphoma, Large-Cell, Anaplastic - pathology
Lymphoma, Large-Cell, Anaplastic - radiotherapy
Male
Middle Aged
Neoplasm Staging
Prednisone - therapeutic use
Prognosis
radiotherapy
Recurrence
Survival Rate
systemic ALCL
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large‐cell lymphoma (ALCL) treated with doxorubicin‐based chemotherapy and radiotherapy. Forty‐six adult patients with early stage systemic ALCL received chemotherapy followed by radiotherapy. All patients except two received chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP‐like regimen. Twenty patients had stage I disease, and 26 patients had stage II disease. The 5‐yr overall survival (OS), progression‐free survival (PFS), and local control rates for all patients were 84.4%, 63.6%, and 90.8%, respectively. The 5‐yr OS and PFS rates were 95.0% and 77.4% for Ann Arbor stage I disease, and 75.1% and 51.7% for stage II disease, respectively. Lymph node involvement was the main pattern of disease progression or relapse for these patients. Adult patients with early stage systemic ALCL treated with doxorubicin‐based chemotherapy and radiotherapy had a favorable prognosis.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.12060